(You may be interested in: Pain or burning when urinating: why does it happen and when to go to the doctor?).
(You may be interested in: Heat waves: why is it important to protect your skin and how to do it?).
Using the compound Telaglenastat (CB-839), the researchers interfered with the function of glutaminase and examined how the carbon and nitrogen atoms present in glutamine were used in metabolic processes within cancer cells. These experiments provided valuable information about the active metabolic pathways in glioblastoma, which could help to better understand its behavior and find new therapeutic strategies.
(It may interest you: Batteries! Vaccine against human papilloma virus would be free for men: this is known).
The study delved into how the metabolism of glioblastoma cells is modified by blocking the activity of glutaminase, looking for weak points at the metabolic level that can be exploited in a combination therapy that includes CB-839.
José Manuel Matés, principal investigator of the research and co-director of the Canceromics group, highlighted that this work is the result of collaboration with the Group led by Professor DeBerardinis (UTSW, in Dallas, United States), one of the world leaders in this field. The collaboration was essential to carry out experiments that required the collaboration of both Centers.
The researcher emphasized the need for a larger budget to optimize cancer research infrastructures in Spain and to be able to progress in this area that affects so many patients and their families, describing this challenge as one of the greatest challenges facing society.
